These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
446 related articles for article (PubMed ID: 32265602)
21. Elexacaftor-Tezacaftor-Ivacaftor: A Life-Changing Triple Combination of CFTR Modulator Drugs for Cystic Fibrosis. Bacalhau M; Camargo M; Magalhães-Ghiotto GAV; Drumond S; Castelletti CHM; Lopes-Pacheco M Pharmaceuticals (Basel); 2023 Mar; 16(3):. PubMed ID: 36986509 [TBL] [Abstract][Full Text] [Related]
22. Regulatory T cell enhancement in adults with cystic fibrosis receiving Elexacaftor/Tezacaftor/Ivacaftor therapy. Westhölter D; Raspe J; Uebner H; Pipping J; Schmitz M; Straßburg S; Sutharsan S; Welsner M; Taube C; Reuter S Front Immunol; 2023; 14():1107437. PubMed ID: 36875141 [TBL] [Abstract][Full Text] [Related]
23. Who are the 10%? - Non eligibility of cystic fibrosis (CF) patients for highly effective modulator therapies. Desai M; Hine C; Whitehouse JL; Brownlee K; Charman SC; Nagakumar P Respir Med; 2022 Aug; 199():106878. PubMed ID: 35633605 [TBL] [Abstract][Full Text] [Related]
24. Challenged Urine Bicarbonate Excretion as a Measure of Cystic Fibrosis Transmembrane Conductance Regulator Function in Cystic Fibrosis. Berg P; Sorensen MV; Rousing AQ; Vebert Olesen H; Jensen-Fangel S; Jeppesen M; Leipziger J Ann Intern Med; 2022 Nov; 175(11):1543-1551. PubMed ID: 36315944 [TBL] [Abstract][Full Text] [Related]
25. CFTR modulator drug desensitization: Preserving the hope of long term improvement. Leonhardt K; Autry EB; Kuhn RJ; Wurth MA Pediatr Pulmonol; 2021 Aug; 56(8):2546-2552. PubMed ID: 33913624 [TBL] [Abstract][Full Text] [Related]
26. Efficacy and Safety of CFTR Corrector and Potentiator Combination Therapy in Patients with Cystic Fibrosis for the F508del-CFTR Homozygous Mutation: A Systematic Review and Meta-analysis. Wu HX; Zhu M; Xiong XF; Wei J; Zhuo KQ; Cheng DY Adv Ther; 2019 Feb; 36(2):451-461. PubMed ID: 30554331 [TBL] [Abstract][Full Text] [Related]
27. Tezacaftor for the treatment of cystic fibrosis. Sala MA; Jain M Expert Rev Respir Med; 2018 Sep; 12(9):725-732. PubMed ID: 30073878 [TBL] [Abstract][Full Text] [Related]
28. Rechallenge of Elexacaftor/Tezacaftor/Ivacaftor After Skin Rash in Two Pediatric Patients. Diseroad ER; Mogayzel PJ; Pan A J Pediatr Pharmacol Ther; 2022; 27(5):463-466. PubMed ID: 35845562 [TBL] [Abstract][Full Text] [Related]
29. Elexacaftor is a CFTR potentiator and acts synergistically with ivacaftor during acute and chronic treatment. Shaughnessy CA; Zeitlin PL; Bratcher PE Sci Rep; 2021 Oct; 11(1):19810. PubMed ID: 34615919 [TBL] [Abstract][Full Text] [Related]
30. Eruptive melanocytic naevi following initiation of elexacaftor/ivacaftor/tezacaftor for cystic fibrosis. Atkinson M; Johnson O; Wilson N; Walshaw M; FitzMaurice TS J Cyst Fibros; 2022 Nov; 21(6):1070-1073. PubMed ID: 35752560 [TBL] [Abstract][Full Text] [Related]
31. Newly Discovered Cutting-Edge Triple Combination Cystic Fibrosis Therapy: A Systematic Review. Dawood SN; Rabih AM; Niaj A; Raman A; Uprety M; Calero MJ; Villanueva MRB; Joshaghani N; Villa N; Badla O; Goit R; Saddik SE; Mohammed L Cureus; 2022 Sep; 14(9):e29359. PubMed ID: 36284811 [TBL] [Abstract][Full Text] [Related]
32. Cystic Fibrosis: A Review. Ong T; Ramsey BW JAMA; 2023 Jun; 329(21):1859-1871. PubMed ID: 37278811 [TBL] [Abstract][Full Text] [Related]
33. L1077P CFTR pathogenic variant function rescue by Elexacaftor-Tezacaftor-Ivacaftor in cystic fibrosis patient-derived air-liquid interface (ALI) cultures and organoids: in vitro guided personalized therapy of non-F508del patients. Lo Cicero S; Castelli G; Blaconà G; Bruno SM; Sette G; Pigliucci R; Villella VR; Esposito S; Zollo I; Spadaro F; Maria R; Biffoni M; Cimino G; Amato F; Lucarelli M; Eramo A Respir Res; 2023 Sep; 24(1):217. PubMed ID: 37674160 [TBL] [Abstract][Full Text] [Related]
34. CFTR pharmacological modulators: A great advance in cystic fibrosis management. Foucaud P; Mercier JC Arch Pediatr; 2023 Jan; 30(1):1-9. PubMed ID: 36509624 [TBL] [Abstract][Full Text] [Related]
35. The Effects of Elexacaftor, Tezacaftor, and Ivacaftor (ETI) on Blood Glucose in Patients With Cystic Fibrosis: A Systematic Review. Salazar-Barragan M; Taub DR Cureus; 2023 Jul; 15(7):e41697. PubMed ID: 37575762 [TBL] [Abstract][Full Text] [Related]
36. CFTR Modulators in People with Cystic Fibrosis: Real-World Evidence in France. Regard L; Martin C; Burnet E; Da Silva J; Burgel PR Cells; 2022 May; 11(11):. PubMed ID: 35681464 [TBL] [Abstract][Full Text] [Related]
37. Prenatal Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy: A Promising Way to Change the Impact of Cystic Fibrosis. Gómez-Montes E; Salcedo Lobato E; Galindo Izquierdo A; García Alcázar D; Villalain González C; Moral-Pumarega MT; Bustos Lozano G; Luna-Paredes C Fetal Diagn Ther; 2023; 50(2):136-142. PubMed ID: 36996799 [TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of lumacaftor and ivacaftor in patients aged 6-11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial. Ratjen F; Hug C; Marigowda G; Tian S; Huang X; Stanojevic S; Milla CE; Robinson PD; Waltz D; Davies JC; Lancet Respir Med; 2017 Jul; 5(7):557-567. PubMed ID: 28606620 [TBL] [Abstract][Full Text] [Related]
39. Phase 1 Study to Assess the Safety and Pharmacokinetics of Elexacaftor/Tezacaftor/Ivacaftor in Subjects Without Cystic Fibrosis With Moderate Hepatic Impairment. Viswanathan L; Bachman E; Tian S; Ahluwalia N; Zhang Y; Bernstein HS; Panorchan P Eur J Drug Metab Pharmacokinet; 2022 Nov; 47(6):817-825. PubMed ID: 36036885 [TBL] [Abstract][Full Text] [Related]
40. Elexacaftor/Tezacaftor/Ivacaftor in Patients with Cystic Fibrosis Homozygous for the Carnovale V; Iacotucci P; Terlizzi V; Colangelo C; Ferrillo L; Pepe A; Francalanci M; Taccetti G; Buonaurio S; Celardo A; Salvadori L; Marsicovetere G; D'Andria M; Ferrara N; Salvatore D J Clin Med; 2022 Feb; 11(4):. PubMed ID: 35207295 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]